Gene expression in blood is associated with risperidone response in children with autism spectrum disorders

Pharmacogenomics Journal

Volumn 12, Issue 5, 2012, Pages 368-371

  Lit, L ^a   Sharp, F R ^a   Bertoglio, K ^b   Stamova, B ^a   Ander, B P ^a   Sossong, A D ^c   Hendren, R L ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

atypical antipsychotic; autism; gene expression; risperidone

Indexed keywords

RISPERIDONE;

ABERRANT BEHAVIOR CHECKLIST IRRITABILITY; ARTICLE; AUTISM; BEDTIME DOSAGE; BEHAVIOR DISORDER; CHILD; CHILD PSYCHIATRY; CHROMOSOMAL LOCALIZATION; CHROMOSOME 16P; CLINICAL ARTICLE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG TOLERABILITY; EXON; FEMALE; GBP6 GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; MALE; MORNING DOSAGE; NFKBID GENE; PHARMACOGENETICS; PRIORITY JOURNAL; RABL5 GENE; RNF213 GENE; RNF40 GENE; SCHOOL CHILD; SCORING SYSTEM; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION STUDIES; HUMANS; INFANT; MALE; RISPERIDONE; TREATMENT OUTCOME;

EID: 84866742795     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.23     Document Type: Article

References (28)

1. des Portes V, Hagerman RJ, Hendren RL. Pharmacotherapy. In: Ozonoff S, Rogers SJ, Hendren RL (eds). Autism Spectrum Disorders: A Research Review for Practitioners. American Psychiatric Association Publishing: Washington, DC, 2003, pp 161-186.
2. Williams SK, Scahill L, Vitiello B, Aman MG, Arnold LE, McDougle CJ et al. Risperidone and adaptive behavior in children with autism. J Am Acad Child Adolescent Psychiatry 2006; 45: 431-439.
3. Bantick RA, Deakin JF, Grasby PM. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 2001; 15: 37-46.
4. Ichikawa J, Meltzer HY. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci 1999; 249(Suppl 4): 90-98.
5. Swann AC. Neuroreceptor mechanisms of aggression and its treatment. J Clin Psychiatry 2003; 64(Suppl 4): 26-35.
6. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2001; 297: 711-717.
7. McDougle CJ, Hollway J, Scahill L, Koenig K, Aman MG, McGough JJ et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005; 162: 1142-1148.
8. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347: 314-321.
9. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114: E634-E641.
10. Pandina GJ, Bossie CA, Zhu Y, Flanders S. The aberrant behavior checklist: use in clinical trials of pediatric autism. J Child Adolescent Psychopharmacol 2006; 16: 661-662.
11. Posey DJ, McDougle CJ. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry 2000; 8: 45-63.
12. Su KP, Wu PL, Pariante CM. A cross-over study on safety of lipid profiles associated with olanzapine and risperidone. Eur Neuropsychopharmacol 2005; 15: S463-S464.
13. Danielyan A, Kowatch RA. Management options for bipolar disorder in children and adolescents. Paediatr Drugs 2005; 7: 277-294.
14. Bottai T, Quintin P, Perrin E. Antipsychotics and the risk of diabetes: a general data review. Eur Psychiatry 2005; 20(Suppl 4): S349-S357.
15. McKee JR, Bodfish JW, Mahorney SL, Heeth WL, Ball MP. Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. J Clin Psychiatry 2005; 66: 1161-1168.
16. Erickson CA, Stigler KA, Posey DJ, McDougle CJ. Risperidone in pervasive developmental disorders. Expert Rev Neurother 2005; 5: 713-719.
17. Stamova B, Xu H, Jickling G, Bushnell C, Tian Y, Ander BP et al. Gene expression profiling of blood for the prediction of ischemic stroke. Stroke 2010; 41: 2171-2177.
18. Sollner T, Bennett MK, Whiteheart SW, Scheller RH, Rothman JE. A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion. Cell 1993; 75: 409-418.
19. Muller DJ, Klempan TA, De Luca V, Sicard T, Volavka J, Czobor P et al. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett 2005; 379: 81-89.
20. Haase J, Killian AM, Magnani F, Williams C. Regulation of the serotonin transporter by interacting proteins. Biochem Soc Trans 2001; 29(Part 6): 722-728.
21. Hanson E, Nasir RH, Fong A, Lian A, Hundley R, Shen Y et al. Cognitive and behavioral characterization of 16p11.2 deletion syndrome. J Dev Behav Pediatr 2010; 31: 649-657.
22. Shen Y, Dies KA, Holm IA, Bridgemohan C, Sobeih MM, Caronna EB et al. Clinical genetic testing for patients with autism spectrum disorders. Pediatrics 2010; 125: e727-e735.
23. Vassos E, Collier DA, Holden S, Patch C, Rujescu D, St Clair D et al. Penetrance for copy number variants associated with schizophrenia. Hum Mol Genet 2010; 19: 3477-3481.
24. Borden KL, Freemont PS. The RING finger domain: a recent example of a sequence-structure family. Curr Opin Struct Biol 1996; 6: 395-401.
25. Sunderman Jr FW. The clinical biochemistry of 50-nucleotidase. Ann Clin Lab Sci 1990; 20: 123-139.
26. Arnold LE, Farmer C, Kraemer HC, Davies M, Witwer A, Chuang S et al. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adolesc Psychopharmacol 2010; 20: 83-93.
27. Correia CT, Almeida JP, Santos PE, Sequeira AF, Marques CE, Miguel TS et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J 2010; 10: 418-430.
28. Ikeda M, Tomita Y, Mouri A, Koga M, Okochi T, Yoshimura R et al. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol Psychiatry 2010; 67: 263-269.